Clinical Trials Logo

Renal Insufficiency, Chronic clinical trials

View clinical trials related to Renal Insufficiency, Chronic.

Filter by:

NCT ID: NCT04794517 Completed - Clinical trials for Chronic Kidney Diseases

Dapagliflozin in Non-diabetic Stage IV CKD

ADAPT
Start date: November 8, 2021
Phase: Phase 2
Study type: Interventional

This is a phase 2b, prospective, randomized, cross-over, double-blind, placebo-controlled trial primarily aimed at assessing whether the SGLT2 inhibitor dapagliflozin ameliorates hyperfiltration and reduces proteinuria as compared to placebo in patients with non-diabetic CKD, with particular focus on those at highest risk of progression to end stage kidney disease (ESKD) because of severe renal insufficiency (Stage IV CKD) and proteinuria (>0.5 g/24 hours). The study will also evaluate renal and systemic mechanisms mediating treatment effects on GFR and will explore biochemical factors possibly mediating these effects.

NCT ID: NCT04791267 Completed - Hypertension Clinical Trials

ENCOMPASS: Expansion Study C

Start date: August 17, 2021
Phase: N/A
Study type: Interventional

Some patients living with multiple long-term health conditions have difficulty accessing the services they need, despite available primary care and community resources. Patient navigation programs may help those with complex health conditions to improve their care and outcomes. Community health navigators (CHNs) are community members who help guide patients through the health care system. CHNs are not health professionals like a doctor or nurse, but they are specially trained to help patients get the most out of their health care and connect them to resources. The ENCOMPASS program of research evaluates a patient navigation program that connects patients living with long-term health conditions to CHNs. To understand if the CHN program can be scaled to a provincial level, the ENCOMPASS program of research is expanding to select primary care settings across Alberta. This study implements and evaluates the CHN program at WestView Primary Care Network in the Greater Edmonton area, Alberta, Canada.

NCT ID: NCT04790617 Completed - Hypertension Clinical Trials

ENCOMPASS: Expansion Study B, RCT

ENCOMPASS
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

Some patients living with multiple long-term health conditions have difficulty accessing the services they need, despite available primary care and community resources. Patient navigation programs may help those with complex health conditions to improve their care and outcomes. Community health navigators (CHNs) are community members who help guide patients through the health care system. CHNs are not health professionals like a doctor or nurse, but they are specially trained to help patients get the most out of their health care and connect them to resources. The ENCOMPASS program of research evaluates a patient navigation program that connects patients living with long-term health conditions to CHNs. To understand if the CHN program can be scaled to a provincial level, the ENCOMPASS program of research is expanding to select primary care settings across Alberta. This study implements and evaluates the CHN program at Calgary West Central Primary Care Network in Calgary, Alberta, Canada.

NCT ID: NCT04790604 Completed - Hypertension Clinical Trials

ENCOMPASS: Expansion Study A, RCT

ENCOMPASS
Start date: January 22, 2021
Phase: N/A
Study type: Interventional

Some patients living with multiple long-term health conditions have difficulty accessing the services they need, despite available primary care and community resources. Patient navigation programs may help those with complex health conditions to improve their care and outcomes. Community health navigators (CHNs) are community members who help guide patients through the health care system. CHNs are not health professionals like a doctor or nurse, but they are specially trained to help patients get the most out of their health care and connect them to resources. The ENCOMPASS program of research evaluates a patient navigation program that connects patients living with long-term health conditions to CHNs. To understand if the CHN program can be scaled to a provincial level, the ENCOMPASS program of research is expanding to select primary care settings across Alberta. This study implements and evaluates the CHN program at Edmonton Oliver Primary Care Network in Edmonton, Alberta, Canada.

NCT ID: NCT04784650 Completed - Diabetes Mellitus Clinical Trials

The Prevalence of Foot Complaints/Problems and Ulcers in a Pre-dialysis Population

Start date: January 31, 2021
Phase: N/A
Study type: Interventional

Diabetes mellitus is one of the main causes of chronic kidney disease (CKD) and an increased risk of foot complications is seen in patients suffering from both DM and CKD. CKD and DM patients share a trilogy of risk factors that contribute to the development of foot ulcers. This trilogy consists of peripheral arterial disease (PAD), neuropathy and an increased susceptibility to infection with an impaired wound healing. Additionally, almost one quarter of adults with CKD have to cope with depression. The aim of our study is to determine the prevalence and types of foot problems in a pre-dialysis population, consisting of both DM and non-DM patients. If possible, risk factors will be determined. The detrimental effects of poor kidney function and foot problems on the quality of life and the general health status will be analyzed. A higher prevalence of PAD, peripheral neuropathy and DM are expected in patients with foot problems compared to those without.

NCT ID: NCT04784351 Active, not recruiting - Asthma Clinical Trials

Prediction of Expected Length of Hospital Stay Using Machine Learning

Start date: March 20, 2021
Phase:
Study type: Observational

This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict length of stay throughout a patient's admission. This algorithm was then validated in a validation cohort.

NCT ID: NCT04779905 Completed - Clinical trials for Chronic Kidney Diseases

Chronic Kidney Disease and Non-alcoholic Fatty Liver Diseases

NAFLD
Start date: February 28, 2021
Phase:
Study type: Observational

Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease worldwide. This disease reportedly affects up to 30% of the general population in Western countries, especially in patients with metabolic syndrome, obesity, and type II diabetes. NAFLD is considered to be an independent risk factor for cardiovascular disease and there is accumulating evidence to support a causative role in the development of chronic kidney disease (CKD). So, we aim first to assess the prevalence of chronic kidney disease in NAFLD patients, secondly to detect the association between hepatic fibrosis and CKD in NAFLD patients

NCT ID: NCT04769687 Recruiting - Clinical trials for Chronic Renal Failure

Symbiotics and Systemic Inflammation in Chronic Kidney Disease

SISMIC
Start date: November 21, 2020
Phase: Phase 2
Study type: Interventional

Main objective: To assess the effectiveness of treatment with symbiotics on the chronic systemic inflammation observed in chronic renal failure 4 months after the start of treatment.

NCT ID: NCT04761016 Active, not recruiting - Obesity Clinical Trials

The Integrated Population (I-POP) Health Trial

I-POP
Start date: April 1, 2021
Phase: N/A
Study type: Interventional

The primary aim of this study is to determine whether community health worker (CHW) navigation improves outcomes of chronic disease and chronic disease risk factors in a low-income, primarily ethnic minority population when combined with an evidence-based population health model as compared to usual care after 10 months.

NCT ID: NCT04759274 Recruiting - Clinical trials for Chronic Kidney Diseases

Diuretic Tuner Clinical Decision Support

Start date: November 20, 2023
Phase: N/A
Study type: Interventional

This purpose of this study is to determine the effectiveness of a mobile phone application in helping to control body swelling in patients with kidney problems. The application will help in the day to day adjustments in diuretic medication dosing. Participants in this study will have an application loaded on to their mobile phone by the study team and be taught how to use it over a 2 hour visit. Participants will need to check their blood pressure and weight daily and enter this information into the mobile phone application every day. Participants will need to follow daily instructions in their medication dosing provided by the application. There will be periodic blood testing. This will happen at 2 weeks, 90 days, and up to 4 other times if necessary. At the end of the study there is a 2 hour study visit during which participants will answer a survey. The total length of the study is 90 days.